Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
- Conditions
- Cytomegalovirus Infection
- Interventions
- Drug: Single arm (ganciclovir and valganciclovir)
- Registration Number
- NCT00730769
- Lead Sponsor
- Salvador Gil-Vernet
- Brief Summary
The objectives of this study were:
1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days of treatment.
2. To compare the exposure to ganciclovir, at steady state, after oral valganciclovir with respect to ganciclovir given intravenously (i.v.).
3. Evaluate the security of this treatment with valganciclovir.
- Detailed Description
SOT recipients (kidney, liver and heart transplant) presenting CMV infection or disease were eligible for inclusion if they were ≥18 years of age and presented a positive CMV antigenemia (pp65) defined as ≥ 20positive cells/105 peripherical blood mononuclear cells (PBMC). Patients excluded were those with severe CMV tissue invasive disease, unable to receive oral medication, absolute neutrophil counts less than 500/ mm3, platelets \<25000 platelets/mm3, Hemoglobin\< 80g/l or estimated glomerular filtration rate\< 10 mL/min (according to the Cockcroft-Gault formula).
Patients received a short induction treatment with ganciclovir i.v (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at the dose of 5 mg/kg/12h, by a peripherical vein infusion of one hour, during 5 days followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg/12h during 16 days, after meals, until complete a total of 21 days of treatment. In patients with impaired renal function ganciclovir i.v. and oral valganciclovir doses were adjusted at each visit according to estimated Glomerular Filtration Rate (GFR) by Cockcroft-Gault equation, as recommended by the manufacturer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
- ≥18 years of age, solid organ transplant recipients.
- presented a CMV infection demonstrated by CMV antigenemia (pp65) defined as ≥ 20positive cells/105 peripherical blood mononuclear cells (PBMC).
- gave written informed consent.
- HIV patients.
- Multiorganic transplant.
- Severe CMV tissue invasive disease.
- Unable to receive oral medication.
- absolute neutrophil counts less than 500/ mm3.
- Platelets <25000 platelets/mm3.
- Hemoglobin< 80g/l.
- Estimated glomerular filtration rate< 10 mL/min (according to the Cockcroft-Gault formula)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single arm Single arm (ganciclovir and valganciclovir) Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
- Primary Outcome Measures
Name Time Method Dissapeareance of CMV (pp65) antigenemia, determined in peripheral blood mononuclear cells (PBMC). Baseline, day 5, 10, 15, 21 of treatment and day 30, 60 and 90 of follow-up.
- Secondary Outcome Measures
Name Time Method Dissapareance of Cytomegalovirus viremia measured by PCR, determined in plasma samples. Basal, day 5, 10, 15 and 21 of treatment and 30, 60 and 90 of treatment. Area under the curve (AUC) of Ganciclovir after ganciclovir i.v. and valganciclovir oral in steady state. Day 5 (ganciclovir i.v) and day 15 (valganciclovir oral)
Trial Locations
- Locations (1)
Hospital Universitari Bellvitge- Transplant Departments (Liver, Heart and Kidney)
🇪🇸L'Hospitalet de Llobregat, Barcelone, Spain